Alembic Pharma allots NCDs on pvt placement basis, totalling Rs 3.5 bn

Drug firm Alembic Pharmaceuticals Friday said it has raised Rs 350 crore through allotment of non-convertible debentures (NCDs) on private placement basis.

"The NCD committee of Alembic Pharmaceuticals Ltd...has allotted 1,500, 9 per cent rated unsecured listed redeemable non-convertible debentures (NCDs)... aggregating to Rs 150 crore under tranche I," Alembic Pharmaceuticals said in a regulatory filing.

The company said it has also allotted 2,000, 9 per cent rated unsecured listed redeemable NCDs...aggregating to Rs 200 crore.

Shares of Alembic Pharmaceuticals were trading 0.42 per cent lower at Rs 615 apiece on BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel